Parkin-mediated Lysine 63-linked Polyubiquitination: a Link to Protein Inclusions Formation in Parkinson's and Other Conformational Diseases?
Overview
Neurology
Physiology
Authors
Affiliations
Most, if not all, neurodegenerative diseases are marked by the presence of ubiquitin-positive protein inclusions. How proteins within these inclusion bodies escape proteasomal degradation despite being enriched with ubiquitin remains a conundrum. Current evidence suggests a relationship between proteasomal impairment and inclusion formation, a persuasive explanation for the inability of the cell to remove ubiquitinated protein aggregates. Alternatively, the formation of ubiquitin-enriched inclusion may be uncoupled from the proteasome. Supporting this, we recently uncovered a novel, proteasomal-independent, catalytic activity for the Parkinson disease (PD)-linked ubiquitin ligase, parkin, that significantly enhances the formation of Lewy body (LB)-like inclusions generated in cultured cells by the co-expression of alpha-synuclein and synphilin-1. This unique activity of parkin mediates a non-classical, lysine (K) 63-linked ubiquitin multichain assembly on synphilin-1 that is distinct from the classical, degradation-associated, K48-linked ubiquitination. Interestingly, two other PD-linked gene products, alpha-synuclein and UCHL1, have recently also been associated with K63-linked ubiquitination. Inclusive of parkin, there are therefore now three PD-related gene products that are known to potentiate K63-linked ubiquitination, thus signalling an important functional relationship between this unique mode of ubiquitin tagging and PD pathogenesis. Mechanistically, the involvement of a "non-degradative" mode of ubiquitination in protein inclusion formation is an attractive explanation for how proteins are seemingly stabilized within inclusions.
Ubiquitin-Proteasome-Mediated Protein Degradation and Disorders of the Central Nervous System.
Hegde A, Timm L, Sivley C, Ramiyaramcharankarthic S, Lowrimore O, Hendrix B Int J Mol Sci. 2025; 26(3).
PMID: 39940735 PMC: 11817509. DOI: 10.3390/ijms26030966.
Protein modification in neurodegenerative diseases.
Ramazi S, Dadzadi M, Darvazi M, Seddigh N, Allahverdi A MedComm (2020). 2024; 5(8):e674.
PMID: 39105197 PMC: 11298556. DOI: 10.1002/mco2.674.
Luo X, Liu Y, Balck A, Klein C, Fleming R NPJ Parkinsons Dis. 2024; 10(1):126.
PMID: 38951523 PMC: 11217404. DOI: 10.1038/s41531-024-00732-z.
Exploring the Role of Ubiquitin-Proteasome System in the Pathogenesis of Parkinson's Disease.
Zhao Y, Lin M, Zhai F, Chen J, Jin X Pharmaceuticals (Basel). 2024; 17(6).
PMID: 38931449 PMC: 11207014. DOI: 10.3390/ph17060782.
Lenzi P, Lazzeri G, Ferrucci M, Scotto M, Frati A, Puglisi-Allegra S Int J Mol Sci. 2024; 25(7).
PMID: 38612739 PMC: 11011529. DOI: 10.3390/ijms25073929.